Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load
- 4 May 2006
- journal article
- Published by Wiley in Journal of Medical Primatology
- Vol. 35 (3) , 165-171
Abstract
Background We previously reported successful therapeutic immunization in a chimpanzee having a relatively low viral load, which was immunized with recombinant plasmid hepatitis B surface antigen (HBsAg) DNA and boosted with recombinant HBsAg encoding canarypox virus. In the present study, we attempted to confirm these findings in an animal with a high virus load.Methods and Results We tested three immunization strategies successively over a 3‐year period. In the first of these, we administered four monthly injections of DNA encoding HBsAg + PreS2 + hepatitis B core antigen (HBcAg) + DNA encoding interleukin (IL)‐12, (given 3 days later), and boosted with canarypox expressing all of the above HBV genes 6 months after initial immunization. No reduction in viral load was observed. In the second trial, we administered lamivudine for 8 weeks, and then began monthly DNA‐based immunization with plasmids expressing the above viral genes; however, viral loads rebounded 1 week after termination of lamivudine therapy. In a third trial, we continued lamivudine therapy for 30 weeks and immunized with vaccinia virus expressing the above viral genes 18 and 23 weeks after the start of lamivudine therapy. Again viral loads rebounded shortly after cessation of lamivudine treatment. Analysis of cell‐mediated immune responses, and their avidity, revealed that DNA‐based immunization produced the strongest enhancement of high avidity T‐cell responses, while recombinant vaccinia immunization during lamivudine therapy enhanced low avidity responses only. The strongest low and high avidity responses were directed to the middle surface antigen.Conclusions Three strategies for therapeutic immunization failed to control HBV viremia in a chronically infected chimpanzee with a high viral load.Keywords
This publication has 28 references indexed in Scilit:
- Low CD8 T-Cell Proliferative Potential and High Viral Load Limit the Effectiveness of Therapeutic VaccinationJournal of Virology, 2005
- Dna Prime/Canarypox Boost—Based Immunotherapy of Chronic Hepatitis B Virus Infection in A ChimpanzeeHepatology, 2001
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Steatosis Hepatis in Celiac DiseaseJournal of Hepatology, 1999
- Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.Journal of Clinical Investigation, 1998
- Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic miceJournal of Hepatology, 1997
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- Hepatitis B Virus ImmunopathogenesisAnnual Review of Immunology, 1995
- Hepatitis B Virus ImmunopathogenesisAnnual Review of Immunology, 1995
- Specific vaccine therapy in chronic hepatitis B infectionThe Lancet, 1994